Replies to post #93 on AngioGenex, Inc. (fka AGGX)

[e-ore]

They filed a Form 10. They're obligated to file 10qs and audited 10ks. Shouldn't be an issue with their new huge accounting firm.

Thanks for the information. I see two things happening here:
1. A reverse split to price them out of the penny stock world.
2. Financing from a large reputable firm that wouldn't touch a non-reporting company at penny stock prices.

I'd get particularly excited if a large reputable firm financed them at this price. Ultimate goal, assuming their unique and patented biotechnology is effective, is uplisting to NASDAQ. Investment from a large reputable firm at this price would imply to me that the firm thinks they might get over the $5 level on their own. That would be nice. I think though that the reverse split first is the most likely scenario.